These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34888611)

  • 61. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
    Wen J; Xu H; Liu R; Chen Q; Dai Y; Xu Y
    Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):24-31. PubMed ID: 32538743
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
    Kovács AF; Eberlein K; Hülsmann T
    Oral Maxillofac Surg; 2009 Jun; 13(2):87-93. PubMed ID: 19430823
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
    Fonseca E; Grau JJ; Sastre J; García-Gómez JM; Rueda A; Pastor M; Lara MA; Navalón M; Berrocal A; Tisaire JL; Cruz JJ
    Eur J Cancer; 2005 Jun; 41(9):1254-60. PubMed ID: 15908196
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A prospective evaluation of 5-fluorouracil plus cisplatin in advanced squamous-cell cancer of the head and neck.
    Dasmahapatra KS; Citrin P; Hill GJ; Yee R; Mohit-Tabatabai MA; Rush BF
    J Clin Oncol; 1985 Nov; 3(11):1486-9. PubMed ID: 4056841
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
    Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M
    Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
    Sun W; Zhang X; Ding X; Li H; Geng M; Xie Z; Wu H; Huang M
    PLoS One; 2015; 10(5):e0125976. PubMed ID: 25973606
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of brachytherapy concomitant with chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in unresectable head and neck squamous cell carcinoma.
    Wang X; Meng J
    J BUON; 2016; 21(3):588-93. PubMed ID: 27569077
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Combined usage of taxotere in induction chemotherapy of head and neck neoplasms].
    Zeng J; Yu QW; Liu WW; Zeng ZY
    Ai Zheng; 2003 Aug; 22(8):877-9. PubMed ID: 12917040
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
    Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
    Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
    Adkins D; Ley J; Trinkaus K; Thorstad W; Lewis J; Wildes T; Siegel BA; Dehdashti F; Gay H; Mehan P; Nussenbaum B
    Cancer; 2013 Feb; 119(4):766-73. PubMed ID: 22991252
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
    Chang PM; Lu HJ; Wang LW; Tai SK; Chen MH; Chu PY; Yang MH
    Head Neck; 2017 Jul; 39(7):1333-1342. PubMed ID: 28370774
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
    Andreadis C; Vahtsevanos K; Sidiras T; Thomaidis I; Antoniadis K; Mouratidou D
    Oral Oncol; 2003 Jun; 39(4):380-5. PubMed ID: 12676258
    [TBL] [Abstract][Full Text] [Related]  

  • 78. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
    Yang CZ; Ma J; Zhu DW; Liu Y; Montgomery B; Wang LZ; Li J; Zhang ZY; Zhang CP; Zhong LP
    Ann Oncol; 2014 Jun; 25(6):1215-22. PubMed ID: 24669014
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sequential therapy of advanced buccal mucosa squamous cell carcinoma: three-year outcome.
    Lyu J; Li C; Wu Y; Wang R; Ren G; Guo W
    J Oral Maxillofac Surg; 2014 Mar; 72(3):606-10. PubMed ID: 24342583
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
    Li X; Lin W; Wang H; Lin W; Lin S; Lin Y
    Med Oncol; 2013 Dec; 30(4):746. PubMed ID: 24122256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.